Kangrui Biotech Completes Series A+ Financing to Advance Ophthalmic First-in-Class Drug Development

VCBeat (WeChat: vcbeat) learned第一时间 that recently, Guangzhou Kangrui Biological Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Kangrui Biological" or "Kangrui"), an innovative company focused on the development of breakthrough First-in-Class therapies for ophthalmic diseases, announced the completion of its Series A+ financing round. This round was led by Boru Capital, with participation from Zhongyin Yuecai, Houkang Jianhua, Ganjiang Boqu and others. The proceeds will mainly be used to advance the clinical development of the company’s core products, expand the pipeline, and drive the research and development of the company's early-stage projects.

Kangrui Biological was established in Guangzhou in October 2012. Currently, a Class 1 new drug pipeline is about to complete Phase I clinical trials in both China and the United States, with multiple investigator-initiated trials (IIT) for different indications being conducted domestically. There are plans to initiate Phase II clinical trials in China and the U.S. for two different indications by the end of the year. This new drug has the potential to become the world’s first eye-drop treatment for ocular neovascular diseases. Another new drug pipeline for the prevention and treatment of cataracts has entered the preclinical development stage, with an anticipated IND application submission by the end of the year.

Kangrui BiologicalSaid: "We are very grateful for the support and trust from Boru Capital, Zhongyin Yuecai, Houkang Jianhua, Ganjiang Boqu, and other investors. This round of investment is crucial for rapidly advancing the company's clinical projects and expanding the product pipeline. China has the highest number of blind people globally, and with the aging population and excessive use of electronic products, the incidence of eye diseases continues to increase annually. The eye is one of the most delicate and complex organs in the body, and the technical threshold for ophthalmic drug development is high. There is a lack of effective treatments both in China and globally. Kangrui Biological has assembled an international technical team dedicated to developing innovative products for ophthalmic diseases, with a product pipeline covering several important blinding eye conditions. Our goal and pursuit is: to enable everyone to enjoy 'Visible'The right."

Ms. Du Hongzhen, Founding Partner of Boru CapitalSaid: "With the upgrading of consumption, the incidence of eye diseases is increasing year by year. There is a lack of innovative drugs independently developed in this field in China. Kangrui Biological focuses on the development of innovative ophthalmic treatment technologies. Its product pipeline has high technical barriers and market prospects and has carried out global patent layout. The founding team has demonstrated global organizational leadership and excellent strategic execution capabilities. They have also established profound academic and technical accumulation in the field of ophthalmic diseases. We look forward to Kangrui making continuous breakthroughs in the field of ophthalmology, promoting product launches as soon as possible, and benefiting numerous patients troubled by ophthalmic diseases."

Kangrui Biological focuses on the development of innovative drugs and cutting-edge treatment technologies in the ophthalmology field. The company boasts an international team of top talents, with core members being high-level professionals graduated from leading universities both in and outside China, possessing extensive experience in biopharmaceutical R&D. All product pipelines are first-in-class innovative drugs independently developed by the company, with global patents. The clinical application follows a dual FDA-NMPA submission pathway, accompanied by numerous IIT studies.

WinDigital Capital is a private equity investment fund focused on China, managing several RMB and USD funds. WinDigital Capital concentrates on investments in the fields of life sciences and biopharmaceuticals, TMT, and core hard technologies. The emerging life science industry driven by informatization, digitalization, and intelligence will be a new driving force for economic growth. We focus on investment opportunities brought by the integration of life sciences and innovative technologies, as well as cutting-edge areas characterized by next-generation technology-driven development. In the field of life sciences and medical technology, WinDigital Capital has invested in outstanding companies including Enovax Pharmaceuticals, Suzhou Qide Pharmaceuticals, Beijing Vantage Biotech, Huinuo Pharmaceuticals, WeDoctor, Boan Pharmaceuticals, and Kangrui Biological. WinDigital Capital was listed in the "Top 10 Most Potential Venture Capital Institutions in China for 2020" released by ChinaVenture.